Latest Developments in Global Plexiform Neurofibromas Treatment Market

Customize Your Report Customize Your Report Buy Now Buy Now Free Sample Report Free Sample Report
back-icon

Back to Report
Home Pharmaceutical Global Plexiform Neurofibromas Treatment Market Latest Developments
Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Latest Developments in Global Plexiform Neurofibromas Treatment Market

  • Pharmaceutical
  • Jul 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
Buy Now Buy Now Request for Sample Request for Sample
Nucleus Nucleus

  • In February 2025, the FDA approved mirdametinib (Gomekli) for adults and pediatric patients aged 2 and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that cannot be fully resected

Browse Related Pages

Banner